CD74 and MIF in EBV-associated malignancies: diagnostic and therapeutic implications

CD74 and its ligand, macrophage migration inhibitory factor (MIF), are highly expressed in several malignancies and contribute to tumor progression, making them attractive targets for cancer diagnosis and therapy. However, the expression of CD74 and MIF and their clinicopathological significance remain unclear in Epstein–Barr virus (EBV)-associated malignancies, including nasopharyngeal carcinoma (NPC) and extranodal natural killer/T-cell lymphoma, nasal type (ENKL). In the present study, we demonstrated that CD74 was predominantly expressed by tumor cells in NPC and ENKL tissues. High CD74 expression in NPC was significantly associated with EBV infection. In addition, serum MIF levels were significantly elevated in patients with NPC and ENKL and showed good diagnostic performance in distinguishing patients from healthy controls. Elevated serum MIF levels were also associated with the presence of B symptoms in patients with ENKL. Furthermore, EBV-positive NPC and ENKL cell lines expressed cell-surface CD74 and secreted MIF in a time-dependent manner. Treatment with a CD74-neutralizing antibody significantly reduced the viability of these cell lines, suggesting that CD74/MIF signaling contributes to tumor growth, possibly through an autocrine mechanism. CD74 knockdown in NPC cells induced transcriptomic alterations involving immune- and inflammation-related pathways. Notably, treatment with an anti-CD74 antibody significantly suppressed the growth of established NPC xenografts in mice. Collectively, these findings suggest that CD74 and MIF represent promising diagnostic biomarkers and that therapeutic strategies targeting the CD74/MIF axis may provide a novel treatment approach for EBV-associated malignancies, particularly NPC and ENKL.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2026-11-18
DOI
https://doi.org/10.1007/s00262-026-04620-8
Primary Topic
Viral-associated cancers and disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CD74 and MIF in EBV-associated malignancies: diagnostic and therapeutic implications

Risa Wakisaka, Hiroki Komatsuda, Shota Sakaue, Hisataka Ominato et al.
2 links
Cancer Immunology Immunotherapy
Viral-associated cancers and disorders
article

CD74 and MIF in EBV-associated malignancies: diagnostic and therapeutic implications

Risa Wakisaka, Hiroki Komatsuda, Shota Sakaue, Hisataka Ominato, Miki Takahara, Toshihiro Nagato, Michihisa Kono, Ryosuke Sato, Ryusuke Hayashi, Takumi Kumai, Akemi Kosaka, Kan Kishibe, Takayuki Ohkuri, Ryusei Yoshino, Hidekiyo Yamaki, Kenzo Ohara, Takahiro Inoue, Tatsuya Hayashi, Hiroya Kobayashi, Hiroyoshi Nozaki
article en

Abstract

CD74 and its ligand, macrophage migration inhibitory factor (MIF), are highly expressed in several malignancies and contribute to tumor progression, making them attractive targets for cancer diagnosis and therapy. However, the expression of CD74 and MIF and their clinicopathological significance remain unclear in Epstein–Barr virus (EBV)-associated malignancies, including nasopharyngeal carcinoma (NPC) and extranodal natural killer/T-cell lymphoma, nasal type (ENKL). In the present study, we demonstrated that CD74 was predominantly expressed by tumor cells in NPC and ENKL tissues. High CD74 expression in NPC was significantly associated with EBV infection. In addition, serum MIF levels were significantly elevated in patients with NPC and ENKL and showed good diagnostic performance in distinguishing patients from healthy controls. Elevated serum MIF levels were also associated with the presence of B symptoms in patients with ENKL. Furthermore, EBV-positive NPC and ENKL cell lines expressed cell-surface CD74 and secreted MIF in a time-dependent manner. Treatment with a CD74-neutralizing antibody significantly reduced the viability of these cell lines, suggesting that CD74/MIF signaling contributes to tumor growth, possibly through an autocrine mechanism. CD74 knockdown in NPC cells induced transcriptomic alterations involving immune- and inflammation-related pathways. Notably, treatment with an anti-CD74 antibody significantly suppressed the growth of established NPC xenografts in mice. Collectively, these findings suggest that CD74 and MIF represent promising diagnostic biomarkers and that therapeutic strategies targeting the CD74/MIF axis may provide a novel treatment approach for EBV-associated malignancies, particularly NPC and ENKL.

Cancer Immunology Immunotherapy
Asahikawa Medical University (JP), Asahikawa University (JP)
Asahikawa Medical University, Japan Society for the Promotion of Science
Good health and well-being
Viral-associated cancers and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon